Abstract: Objective To evaluate the therapeutic efficacy and safety of Anfate (Compound Embryonic Bovine Liver Extract Tablets) in patients with non-alcoholic fatty liver disease (NAFLD) .Methods A multicenter, open, non-randomized clinical trial was performed on 240 NAFLD patients with overweight and/or central obesity (male:95, female:45, average age: (42.2±11.3) years) and the patients were treated with Anfate (240 mg p.o bid for 12 weeks) on the base of combined therapy.Results The improvement rate of clinical symptoms was 85.9% (164/191) .Malaise in hepatic region improved most.The ALT was significantly improved in 68.5% (126/184) of the patients, from (79.59±43.63) U/L before treatment down to (43.99±14.83) U/L after treatment (P<0.01) .AST, GGT, TG, TC and LDL-C also had a significant improvement.HDL-C, FBG and HOMA-IR did not show a significant change (P>0.05) .Fatty liver levels decreased one or more than one degree by B-ultrasound in 35.4% (85/240) patients.The liver spleen ratio significantly increased from 0.78±0.18 before treatment to 0.93±0.16 after treatment by CT in 74 patients (P<0.001) .Patients with Anfate treatment group were divided into two as diet control group and increased exercise group.BMI, waist hip ratio (WHR) , ALT, AST, GGT, TG, TC in both groups were all significantly decreased (P<0.001) and more quickly in the former group.Adverse reaction rate was 4.58% (11/240) and most of them showed digestive tract symptom.Conclusion Anfate has a good clinical effect on NAFLD and has no marked toxic or other side effect.